---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-24-001427"
form_type: "8-K"
ticker: null
cik: "0001708331"
company_name: "Virpax Pharmaceuticals, Inc."
filed_at: "2024-09-17T23:59:59+00:00"
generated_at: "2026-05-31T04:17:33.279589+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Virpax board member Vanila M. Singh resigns effective Sept 16, 2024

## Summary
- Vanila M. Singh, MD, resigned from the Board on September 16, 2024, effective immediately.
- No reason for resignation was provided in the filing.
- No replacement has been announced at this time.

## SEC filing metadata
- accession: 0001731122-24-001427
- form_type: 8-K
- cik: 0001708331
- company_name: Virpax Pharmaceuticals, Inc.
- filed_at: 2024-09-17T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708331/000173112224001427/0001731122-24-001427-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708331/000173112224001427/e5951_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-24-001427
- JSON: https://secwatch.observer/filing/0001731122-24-001427.json
- Plain text: https://secwatch.observer/filing/0001731122-24-001427.txt

## Key facts
- Executive change
  Vanila M. Singh resigned as member of the Board of Directors at Virpax Pharmaceuticals, Inc..
  - Action: resigned
  - Role: member of the Board of Directors
  source text: On September 16, 2024, Vanila M. Singh, MD, a member of the Board of Directors (the “Board”) of Virpax Pharmaceuticals, Inc. (the “Company”), notified the Company of her intention to resign from the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708331/000173112224001427/0001731122-24-001427-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.